Document is current
Any future updates will be listed below
-
Authors
Luo, Xiqing
Zhou, Liuzhong
Wen, Xianghui
Li, Jinwei
Liu, Dong
Liu, Budian
Wen, Shenghui
Gu, Jieruo https://orcid.org/0000-0002-8785-0600
-
Funding
Funding for this research was provided by:
Guangdong Clinical Research Center of Immune disease (2020B1111170008)
Key-Area Research and Development Program of Guangdong Province (2023B1111030002)
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 23 September 2025
First Online: 29 December 2025
Declarations
:
: The original source of the cells (Guangzhou Hui Shan Biotechnology Co., Ltd) has obtained initial ethical approval for the collection of human cells (ethics number GT-2021–002-01), and the donors have signed informed consent.All human participants provided written informed consent prior to participation. The study was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China (approval number: [2020] 02–033-01, Studies on immune function assessment and testing in relation to immunological diseases). The animal study was approved by the Guangdong Huawei Testing Co., LTD (approval number: 202407004, The treatment of SKG mouse, 20240704). Animal experiments were performed according to the ARRIVE guidelines 2.0, and all efforts were made to minimize animal suffering.
: All participants consented to the publication of anonymized research findings.
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
